Shares of uniQure N.V. (NASDAQ:QURE) experienced a modest increase on Wednesday, following a significant drop in the previous trading session. The decline was triggered by an unfavorable advisory from the U.S. Food and Drug Administration (FDA) regarding the company’s gene therapy candidate for Huntington’s disease, known as AMT-130. This advisory raised doubts about the therapy’s regulatory pathway, leading to increased uncertainty for investors.
On Monday, the FDA recommended that uniQure conduct a new, rigorous study to support its marketing application for AMT-130. Specifically, the agency suggested a prospective, randomized, double-blind, sham surgery-controlled trial. This recommendation underscores the challenges uniQure faces as it attempts to bring its innovative therapies to market. The company has announced plans to request a Type B meeting with the FDA in the second quarter of 2026 to further discuss the therapy’s development.
Market Performance and Analyst Insights
Despite the recent turbulence, uniQure is advancing its pipeline of gene therapies aimed at treating severe conditions, including Huntington’s disease, refractory temporal lobe epilepsy, amyotrophic lateral sclerosis (ALS), and Fabry disease. Currently, the stock is trading at approximately $9.16, representing a rise of 1.50% on Wednesday. However, it remains 14.29% below its 20-day simple moving average (SMA) and 30.00% below its 100-day SMA, indicating a bearish trend.
Over the past year, shares of uniQure have diminished significantly, positioning them closer to their 52-week low of $7.76 than their high. The relative strength index (RSI) sits at 50.00, reflecting neutral territory, while the moving average convergence divergence (MACD) is at -0.10, suggesting ongoing bearish pressure. This combination of metrics indicates mixed momentum for the stock.
Analysts have mixed sentiments about uniQure’s prospects. The stock currently carries a Buy rating with an average price target of $39.69. Recent adjustments by analysts include:
– Goldman Sachs: Changed to Neutral with a target of $9.00 on March 3.
– Wells Fargo: Downgraded to Equal-Weight, lowering the target to $15.00 on March 3.
– Chardan Capital: Maintained a Buy rating but adjusted the target to $16.00 on March 3.
Future Outlook
As uniQure navigates these regulatory challenges, the focus will be on how effectively the company can address the FDA’s recommendations. The upcoming Type B meeting could be pivotal in shaping the future of AMT-130 and the broader pipeline of gene therapies. Investors will be closely monitoring these developments as they look for signs of recovery in the stock’s performance.
While the recent advisory from the FDA has introduced uncertainty, uniQure’s commitment to advancing its innovative treatments for severe diseases remains strong. The next steps in the therapy’s development will be crucial for both the company and its investors as they seek clarity in a complex regulatory landscape.
